Cargando…

Survivin Small Molecules Inhibitors: Recent Advances and Challenges

Survivin, as a member of the inhibitor of apoptosis proteins (IAPs) family, acts as a suppressor of apoptosis and plays a central role in cell division. Survivin has been considered as an important cancer drug target because it is highly expressed in many types of human cancers, while it is effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Albadari, Najah, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919791/
https://www.ncbi.nlm.nih.gov/pubmed/36771042
http://dx.doi.org/10.3390/molecules28031376
_version_ 1784886911474597888
author Albadari, Najah
Li, Wei
author_facet Albadari, Najah
Li, Wei
author_sort Albadari, Najah
collection PubMed
description Survivin, as a member of the inhibitor of apoptosis proteins (IAPs) family, acts as a suppressor of apoptosis and plays a central role in cell division. Survivin has been considered as an important cancer drug target because it is highly expressed in many types of human cancers, while it is effectively absent from terminally differentiated normal tissues. Moreover, survivin is involved in tumor cell resistance to chemotherapy and radiation. Preclinically, downregulation of survivin expression or function reduced tumor growth induced apoptosis and sensitized tumor cells to radiation and chemotherapy in different human tumor models. This review highlights the role of survivin in promoting cellular proliferation and inhibiting apoptosis and summarizes the recent advances in and challenges of developing small-molecule survivin inhibitors.
format Online
Article
Text
id pubmed-9919791
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99197912023-02-12 Survivin Small Molecules Inhibitors: Recent Advances and Challenges Albadari, Najah Li, Wei Molecules Review Survivin, as a member of the inhibitor of apoptosis proteins (IAPs) family, acts as a suppressor of apoptosis and plays a central role in cell division. Survivin has been considered as an important cancer drug target because it is highly expressed in many types of human cancers, while it is effectively absent from terminally differentiated normal tissues. Moreover, survivin is involved in tumor cell resistance to chemotherapy and radiation. Preclinically, downregulation of survivin expression or function reduced tumor growth induced apoptosis and sensitized tumor cells to radiation and chemotherapy in different human tumor models. This review highlights the role of survivin in promoting cellular proliferation and inhibiting apoptosis and summarizes the recent advances in and challenges of developing small-molecule survivin inhibitors. MDPI 2023-02-01 /pmc/articles/PMC9919791/ /pubmed/36771042 http://dx.doi.org/10.3390/molecules28031376 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Albadari, Najah
Li, Wei
Survivin Small Molecules Inhibitors: Recent Advances and Challenges
title Survivin Small Molecules Inhibitors: Recent Advances and Challenges
title_full Survivin Small Molecules Inhibitors: Recent Advances and Challenges
title_fullStr Survivin Small Molecules Inhibitors: Recent Advances and Challenges
title_full_unstemmed Survivin Small Molecules Inhibitors: Recent Advances and Challenges
title_short Survivin Small Molecules Inhibitors: Recent Advances and Challenges
title_sort survivin small molecules inhibitors: recent advances and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919791/
https://www.ncbi.nlm.nih.gov/pubmed/36771042
http://dx.doi.org/10.3390/molecules28031376
work_keys_str_mv AT albadarinajah survivinsmallmoleculesinhibitorsrecentadvancesandchallenges
AT liwei survivinsmallmoleculesinhibitorsrecentadvancesandchallenges